Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. One of its ...

The failure of Pfizer Inc.’s obesity pill, its highest profile experimental drug, raises the odds that the drugmaker will ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

As President Trump prepares to announce pharmaceutical tariffs, he has one country, in particular, in his sights: Ireland.

Pfizer is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia ...

The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) has a reputation for being the go-to choice for income-focused investors ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

Pfizer Inc. dejará de desarrollar una píldora contra la obesidad que ha sido seguida de cerca por los inversores, un duro ...

Im Ringen um den stark umkämpften Markt für Adipositas-Medikamente hat der US-Pharmakonzern Pfizer einen Rückschlag erlitten ...